Boehringer Ingelheim Vetmedica has launched a series of information sheets written by veterinary surgeons, nutritionists and leading riders to support its muscle building supplement for horses, Equitop Myoplast Power Pearls.

Available to download as PDFs from its website - http://www.equitop-myoplast.co.uk - this resource for horse owners covers a range of feeding topics including training the young showjumper and feeding the performance horse, older horses and horses during periods of rest and recuperation.

New video and written testimonials from performance riders and veterinary surgeons are now on the website, which also offers owners advice on healthy lean muscle growth and the benefits of Equitop Myoplast.  Olympic dressage rider, Emile Faurie, international showjumpers, Ellen Whitaker and Scott Brash, and show horse producer, Katie Jerram, all endorse the product.

A client leaflet has also been launched featuring the testimonials and providing owners with information on Equitop Myoplast and an online offer of £15 off their first purchase of the supplement by downloading a voucher from the website.

Boehringer says Equitop Myoplast is packed with 18 key amino acids and is scientifically designed to support lean muscle growth, not bulk.  The company says the supplement is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.

For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.

DG Sanco, the EU Directorate General for Health and Consumers, has launched a worldwide photo competition to mark World Vet Year: 'Vets in your daily life'

Entries need to be photos of a vet (or vets) at work or in any situation which shows the diverse nature of the job. Five winners will win 1000 Euros worth of photographic equipment. The overall winner will win an additional 2000 Euros worth of photographic equipment. All winners will also be given travel and accommodation for the awards ceremonies in Paris and Brussels.

Anyone (except for employees of the European Institutions, and their families) can enter the competition, which closes on 31st March 2011. More details can be found at: www.vetsinyourdailylife.org.

Here's the promotional video for the competition:

The Horserace Betting Levy Board (HBLB) has launched an online version of the Codes of Practice on equine diseases, ready for the 2011 Thoroughbred breeding season.

The website, codes.hblb.org.uk is a replica of the 2011 booklet, but with an easy to use navigator and built-in text search.

The 2011 online Codes of Practice set out minimum recommendations for the prevention and control of disease. Applying to all breeds of horse and pony, and to both natural mating and AI, the Codes cover:

• Contagious equine metritis (CEM)
• Equine viral arteritis (EVA)
• Equine herpesvirus (EHV)
• Equine coital exanthema (ECE)
• Equine infectious anaemia (EIA)
• Guidelines on strangles

The increasing mobility of horses creates a subsequent increased risk of spreading infectious disease. In recent years, most countries with active horse populations have seen incidents of these diseases, including in Britain the notifiable diseases of CEM, EIA and EVA.

Any of these diseases can have serious consequences for horse and pony breeding, compromising welfare, disrupting breeding activity and causing economic loss and distress.

Professor Willie Donachie, Chairman of the HBLB's Veterinary Advisory Committee said: "We recognise the changing ways in which vets, studs and individual breeder's access information. The new online version of the Codes is designed to reflect this and ensure that the Codes of Practice, a vital resource, are available where and when they are needed."

Equine vets and farriers in South Wales who need horses x-rayed can now use a new mobile service offered by Equiray. Operating 24 hours a day, 7 days a week, Equiray's technicians travel to the site to take digital x-rays, using state-of-the-art imaging equipment.

At the heart of Equiray's service is the Uno Equine portable digital x-ray system; the only system in the world that has a capture screen built into the generator. All images taken can be viewed within minutes and decisions made there and then regarding further tests. The x-ray images are emailed to the veterinary surgeon immediately, or supplied to the practice on a CD or memory stick. They are also stored securely by Equiray for a 3 month period.

For farriers, the image can be displayed on screen so they can see the internal bone structures encapsulated within the hoof before they start remedial work, and then another x-ray taken after the work has been completed. Both images can be viewed together for comparison.

Equiray says its service means practices don't have to buy and maintain costly equipment, nor send a practice technician to attend with the vet, as all Equiray technicians are highly skilled in equine imaging.

Equiray currently operates mainly in South Wales but with requests coming from other areas of the country, the company says its technicians are travelling to x-ray several horses in a particular area, over a 2 day period. Remedial farriers requiring monthly x-rays of certain horses are also using the service and plans to extend the service nationally are in progress.

For more information, visit www.equiray.co.uk/

Novartis Animal Health has announced that it will begin marketing and distributing Adequan Equine in the UK from January 2011.

According to the company, Adequan Equine offers equine veterinarians a proven intramuscular treatment option for equine degenerative joint disease, also known as non-infectious arthritis or osteoarthritis. The product is licensed in the UK for the treatment of lameness in horses due to traumatic or degenerative aseptic joint disease and acute superficial digital flexor tendonitis. This is a critical treatment area since equine degenerative joint disease is estimated to cause up to one-third of all equine lameness cases1. It most commonly affects the hocks and coffin joints with the most severe effects on the high-motion knee and fetlock joints.

Esther Rawlinson MRCVS, Global Technical Services Manager for the Novartis Animal Health Companion Animal Business in the Therapeutics & Equine areas said: "Adequan Equine is a leading joint treatment for horses and is widely used by veterinarians in the equine sport industry. Adequan Equine reduces pain and lameness in horses while at the same time stimulating cartilage repair.

Adequan Equine 100mg/ml solution contains polysulphated glycosaminoglycan for intramuscular injection. It is a chondroprotective, meaning it inhibits the breakdown of cartilage in diseased joints while at the same time supporting its repair.

Adequan Equine works by blocking the destructive enzymes formed in the joint as a result of inflammation while stimulating the production of hyaluronic acid to restore the synovial fluid, and the synthesis of cartilage building compounds.

Pfizer Animal Health is advising vets and horse owners to be on guard against the threat of West Nile Virus (WNV) in the UK, following a spate of outbreaks of the disease in several European countries this year.

West Nile Virus has recently made headline news because of a human outbreak in Greece which resulted in a number of deaths. Outbreaks have also occurred in Russia, Romania and Italy during 2010. West Nile Fever is a viral disease transmitted by mosquitoes, which carry the virus after biting infected birds. Primarily occurring between July and October, in line with typical peak activity of mosquitoes, it can have serious consequences on human and equine health, with severe cases resulting in fatal neurological disease.

There is no cure, though supportive treatment can aid recovery. However if the disease progresses to a state where the animal is not able to stand up, their chance of survival is considered low. Prevention of infection is difficult, but any steps that reduce mosquito numbers or the likelihood of horses and people being bitten may help to reduce the risk in areas where the disease is present. However, the only way to reduce the risk of an individual horse developing disease due to WNV is through vaccination.

Ben Gaskell, Pfizer's equine veterinary advisor said: "West Nile Virus may well become a very real threat to both horses and humans in Northern Europe. It is important for vets, horse owners and infectious disease experts to work together to mitigate its impact in the event of the virus becoming endemic across Europe. The rapid spread of the disease across North America is an illustration of what could potentially happen in Europe and it is important to remember there is no curative treatment - the only way to prevent clinical disease in horses is by vaccination." 

Pfizer Animal Health supports the PrEquID (Prevention of Equine Infectious Disease) group, which consists of internationally recognised equine and infectious disease experts. The group was formed to develop guidelines on the prevention and control of a number of equine infectious diseases, on a global basis. 

Klaus Osterrieder, Professor and Chair in the Institut für Virologie in the Veterinärfakultät at Freie Universität Berlin, Germany and a member of the PrEquID group advises: "Horse owners should ask their veterinarian for advice on appropriate prevention measures.  Experience has shown that adopting a prudent prevention strategy can be a very effective way of managing this devastating disease."

Further information on WNV is available at www.westnile.eu.

Ceva Animal Health has produced a new booklet explaining the discharge procedures for horses that have been treated with Equidronate (formerly called Tildren), a bisphosphonate infusion used for the treatment of bone spavin.

Ceva says the new booklet is designed for vets to give their clients to help convey the most effective post-treatment management protocol. It explains what Equidronate is, how it works and how it is administered. It goes on to cover how owners can help to monitor progress once exercise has commenced, by completing the specially created assessment forms contained within the booklet every couple of weeks.

According to the company, trials published earlier this year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.

Copies of the new leaflet are available free of charge from your Ceva sales representative. Leaflets on understanding bone spavin, understanding navicular disease and understanding sacroiliac disease are also available.

Boehringer Ingelheim Vetmedica has launched Prascend, the first licensed product for the treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses, commonly known as Equine Cushing's Disease.

Prascend contains pergolide mesylate, and is supplied in 60 and 160 tablet packs of 1mg tablets.

Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Many horses and ponies with Cushing's Disease benefit from treatment with pergolide, however, with less than 200 people still being treated with pergolide in the UK, many vets and horse owners have expressed concern that they will not be able access treatment in the future.

"We have invested in dedicated veterinary manufacturing of this product, and can assure our customers that the future supply of Prascend is guaranteed irrespective of any changes of in the human generic market."

For further information, visit www.prascend.co.uk or call 01344 746959

A research project funded by The Horse Trust has discovered that a racehorse's performance does not markedly change after it has recovered from a tendon injury.

The research was led by Bryan O'Meara, who is in the final year of a three year clinical training scholarship funded by The Horse Trust.

Mr. O'Meara carried out the research at Donnington Grove Veterinary Surgery in Newbury, under the supervision of epidemiologist Dr Tim Parkin from University of Glasgow.

Tendonitis is one of the most common musculoskeletal injuries in racehorses, with a prevalence of 11-30%, according to earlier research.

Mr. O'Meara examined the clinical records and racing histories of 400 racehorses who had been treated for superficial digital flexor (SDF) tendonitis injuries over a five year period (2003-2008).

The race records of horses affected by tendon injury were compared with 400 matched control horses that had never suffered SDF tendon injuries.

The controls were horses training in the same establishment at the time of injury and of the same age and sex as the case horse.

The research looked at the performance of the racehorses in races before and after treatment for the injury, and at the performance of the control horses before and after the treatment date. The Racing Post Rating (RPR), which is published by the Racing Post after every race, was used as a measure of performance.

Mr. O'Meara found that there was no significant difference in RPR before and after the treatment date in case and control horses.

According to The Horse Trust, this result is unexpected as in vitro studies have found that healed tendon tissue has reduced elasticity due to the presence of scar tissue. This suggests that a horse with a healed SDF tendon would need to work its muscles harder to compensate and would therefore be expected to have lower performance.

Mr. O'Meara said more research is needed to back-up his finding that performance isn't significantly affected by tendon injury: "It could be that using Racing Post Rating to measure performance isn't sensitive enough to pick up a change in the horse's performance. However, it's encouraging that there's no marked change in performance after a horse has recovered from a tendon injury. These findings show that there's no need to give up on a horse that has a tendon injury - they can still come back and perform well, or can be used for other, less demanding riding activities."

The research also found that there was no significant difference between case and control horses when returning to racing and completing three races. Only after completing five races, or three years post treatment, was a significant difference found between case and control horses. This finding is a step towards developing a more accurate assessment of tendon treatment. Outcome after five races or three years post treatment is a better indicator of the outcome of treatment.

Mr. O'Meara said: "At the moment, some tendon treatments state their success as the percentage of horses that return to racing after treatment. However, we've shown that there's no significant difference between case and control horses at this time. At the moment, there are a myriad of treatments available to treat tendonitis. Hopefully this finding will be used in further research to learn which treatments are most effective."

Mr O'Meara's research also found a link between SDF tendon injury and the racehorse competing at its maximum performance level: the case horses were significantly nearer to their pre-injury maximum performance level in the race immediately before injury (compared to matched controls), suggesting that they were competing nearer their individual maximum performance level when the SDF tendon injury occured.

Intervet/Schering-Plough Animal Health has announced that it is to sponsor the Equine Business Management Strategies (EBMS) program, a targeted business education program developed for equine veterinary surgeons and practice professionals.

According the company, this 5-day course has proven very successful in the United States. It had its European kick-off in Amsterdam on August 22, 2010, where a group of almost forty equine practitioners from North America and Europe gathered to discuss and learn how to apply business principles in their day-to-day work. The program was chaired by Dr. Joop Loomans, an equine veterinary surgeon responsible for equine business management education at the Department of Equine Sciences of the Veterinary Faculty of Utrecht University (The Netherlands).

Course participants worked with international specialists on strategic planning, benchmarking, branding and change management to create strategic plans to implement at their practices, and to share their knowledge, experience and ideas.

Intervet/Schering Plough says the launch of Equine Business Management Strategies program exceeded expectations of participants, sponsor and organizers. The chance to look at the day-to-day practice from a different angle and to learn about things like benchmarking exercises, revenue analysis and branding was highly appreciated. Participant Jeremy Mantell from Liphook Equine Hospital in the UK said: "The EBMS has given me a clearer understanding of what I need to change and develop in my practice."

Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering-Plough Animal Health said: "We believe that running an equine practice is not based solely on technical and scientific skills but also on effective practice management. That is why our company has decided to support this initiative. Intervet/Schering-Plough Animal Health also continues its custom of providing not only innovating products, but also new, value-added services to strengthen its bond with veterinarians."

Every UK-based veterinary surgeon that registers as a member of www.vetsurgeon.org by 1st November 2010 will be entered into a draw to win an Apple iPad 32GB Wi-Fi worth £500.

All existing veterinary surgeon members will also be entered into the draw automatically, so there's no need to re-register. Still, you might like to spread the word about the draw amongst colleagues.

Full terms and conditions are available by clicking here.

Equine infectious anaemia (EIA) has been detected in a horse in Northumberland following importation from the Netherlands, Defra confirmed today.

The premises is currently under restriction and the infected horse will be humanely destroyed in line with existing regulations. The other horses on the premises are currently subject to epidemiological investigation.

The horse arrived in a group of six horses originating in the Netherlands and all have been tested for EIA as part of routine post-import testing. The other five horses in the group have all tested negative.

Chief Veterinary Officer Nigel Gibbens said: "This again shows the success of our post import testing regime. These were apparently healthy horses carrying a notifiable disease that we are keen to keep out of Great Britain. After considering the risk I have decided to take appropriate action and humanely destroy this horse."

Meanwhile, equine welfare charity World Horse Welfare is sending out an urgent plea to all horse owners across the UK and mainland Europe to work together in order to stop the increasing threat from this and a number of other diseases.

According to the charity, this case comes only eight months after the discovery of two horses suffering from the disease, which is notifiable, in Wiltshire. Those horses had been transported across Europe from Romania before being imported into the UK.  Since the end of August alone, there have been new outbreaks reported in Northern France (directly linked to horses imported from Romania), the Dordogne area, and Germany. 

World Horse Welfare Chief Executive Roly Owers said: "While World Horse Welfare welcomes the news that Defra has acted so promptly in dealing with this case, today's news is extremely concerning and demonstrates the changing environment we're living in. This is a real warning to us that we're sailing far too close to the wind.  The concerning question is where these horses came from given that Holland to date has not reported a case of EIA.

"With more and more horses moving across Europe, including the significant trade in low value animals, not just slaughter animals, we're facing an increasing threat from the spread of disease.  EIA is endemic in both Romania and Italy; Romania being one of the largest exporters and Italy being the largest importer of horses for slaughter in Europe.  In spite of the legal requirement for health certification before exporting horses from Romania, which were tightened in June 2010, there continues to be cases of EIA across Europe.

"World Horse Welfare advises owners to undertake rigorous checks when buying a horse from abroad and is discouraging anyone from importing Romanian horses. Owners should also ensure that any horse they buy or that comes on to their yard has a passport, is checked for a microchip and that isolation and biosecurity measures are strictly followed for any new entry onto the yard. If this disease spreads across the UK it could have catastrophic effects on our horse population.  Whether it's a child's pony or Cheltenham Gold Cup winner, disease does not discriminate."